TNI BioTech, Inc,  earlier announced that its pharmaceutical sales division, Airmed Biopharma Limited, ("Airmed"), a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc.to market Lodonal.

In the press release, TNI BioTech and Airmed reported receipt of an initial purchase order for $150,000 and that by the agreement, PanAm seeks to distribute a minimum of 5,000 pills per month for the balance of the year with sales expected to increase in 2015. In fact, PanAm seeks to distribute a minimum of 5,000 'cartons' per month, or 150,000 pills per month, for the balance of the year with sales expected to increase in 2015.

TNI BioTech and Airmed reiterate that Airmed will deliver the first shipment by July 7, 2014. TNI BioTech and Airmed reiterate their estimate that the agreement will generate approximately $1,800,000 in revenue in year one of the distribution relationship. TNI BioTech and Airmed thank PanAm for pointing out this correction.

TNI BioTech is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Our proprietary technology, therapies and patents include the treatment of a wide range of cancers. Our most advanced clinical programs involve immunotherapy with met-enkephalin ("MENK") (sometimes referred to as opioid growth factor ("OGF")) and our Low Dose Naltrexone product ("LDN") or Lodonal, which have been shown to stimulate the immune system even in patients with advanced cancer.

Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.

Airmed Biopharma Limited, a wholly owned Irish company, is the pharmaceutical sales division of TNI BioTech. Airmed is responsible for servicing sales orders for Lodonal in countries where TNI BioTech has received sales approval in Latin America and Africa.

Cytocom, Inc. is a biotechnology company that will initially focus on developing Low Dose Naltrexone (Lodonal) and met-enkephalin in the investigation of unmet medical needs in the areas of oncological and inflammatory diseases.